The addition of the AKT inhibitor capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy (ADT) ...
CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant after first-line CDK4/6 ...
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today reported financial results for the full year ended December 31, 2025, ...
Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they typically work for only 40% to 80% of the patients who would be expected to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results